That's what happened beginning in November of last year, anyway. The company announced solid testing results for VK2735. But ...

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over vaccine limits, venture funding for digital health, and more.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts.